(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 March 2015 (05.03.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/031698 A8

(51) International Patent Classification:
A61K 39/00 (2006.01) *C12P 21/08* (2006.01)
A61K 39/395 (2006.01) *C07K 16/00* (2006.01)

(21) International Application Number:
PCT/US2014/053310

(22) International Filing Date:
28 August 2014 (28.08.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/871,173 28 August 2013 (28.08.2013) US
61/871,289 28 August 2013 (28.08.2013) US
PCT/US2014/053014
27 August 2014 (27.08.2014) US

(71) Applicant: **STEMCENTRX, INC.** [US/US]; 450 East Jamie Court, South San Francisco, California 94080 (US).

(72) Inventors: **ARATHOON, William Robert**; 129050 Brendel Dr., Los Altos Hills, California 94022 (US). **PADAWER, Ishai**; 925 Fell St. Apt. 4, San Francisco, California 94117 (US). **CANO, Luis Antonio**; 2131 Melvin Rd, Oakland, California 94602 (US). **SISODIYA, Vikram Natwarsinhji**; 3615 22nd St. Apt 23, San Francisco, California 94114 (US). **MANI, Karthik Narayan**; 1264 9th Ave., San Francisco, California 94122 (US). **LIU, David**; 300 Santa Rosa Avenue, Apt. 1, San Francisco, California 94112 (US).

(74) Agents: **MEIGS, Julie Broadus** et al.; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia 30357-0037 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
3 December 2015

(15) Information about Correction:
see Notice of 3 December 2015

(54) Title: SITE-SPECIFIC ANTIBODY CONJUGATION METHODS AND COMPOSITIONS

(57) Abstract: Provided are antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders. In some aspects, the disclosure provides engineered antibodies that immunospecifically react with a determinant on tumor initiating cells, such as DLL3, SEZ6, or CD324. The antibodies comprising one or more unpaired cysteine residues provide site(s) for the selective and controlled conjugation to a therapeutic or diagnostic agent.

WO 2015/031698 A8